NEW YORK (GenomeWeb) – Cancer diagnostics firm Biodesix has raised $8.6 million in promissory notes, according to a document filed recently with the US Securities and Exchange Commission.

The firm disclosed that it seeks to raise up to $20 million and that it has so far raised $8.6 million in promissory notes convertible into equity securities.

The firm did not disclose what it would use the funds for or the identities of the investors in the financing. It said that 18 investors have participated in the financing. Biodesix did not respond to requests seeking comment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.